Related Experiment Videos
[Gynecologic brachytherapy--from low-dose-rate to high-tech]
T Herrmann1, N Christen, H D Alheit
1Abteilung Strahlentherapie, Medizinische Akademie Carl Gustav Carus, Dresden.
Summary
High-dose-rate (HDR) brachytherapy offers comparable local control and side effect profiles to low-dose-rate (LDR) brachytherapy for cervical cancer. HDR brachytherapy presents advantages for patients, radiation oncologists, and radiation protection.
Area of Science:
- Radiation Oncology
- Gynecologic Oncology
- Medical Physics
Background:
- The shift from low-dose-rate (LDR) to high-dose-rate (HDR) brachytherapy is a growing trend in radiation therapy centers.
- Initial studies suggest comparable local control rates between HDR and LDR treatments for cervical cancer.
Purpose of the Study:
- To compare the efficacy and safety of HDR versus LDR brachytherapy in patients with primary cervical carcinoma.
- To evaluate local control rates and radiogenic late effects between the two brachytherapy modalities.
Main Methods:
- Retrospective analysis of 319 patients with primary irradiated cervical carcinoma.
- Categorization of patients into HDR (125 patients) and LDR (194 patients) groups.
- Assessment of control rates by FIGO stage and side effects using EORTC/RTOG criteria.
Main Results:
- Local control rates for FIGO Stage I were 95.4% for HDR versus 82.9% for LDR (not significant).
- Control rates for Stage II (71.4% HDR vs. 73.7% LDR) and Stage III (57.9% HDR vs. 38.5% LDR) showed no significant differences.
- No significant differences in serious radiogenic late effects on the intestine, bladder, and vagina were observed between HDR and LDR groups.
Conclusions:
- HDR brachytherapy demonstrates at least equivalent results to LDR brachytherapy for cervical cancer regarding local control and side effects.
- HDR brachytherapy offers advantages for patient management, radiation oncologists, and radiation protection.
- Radiobiological considerations suggest fractionation is key in HDR for normal tissue sparing, advocating for more smaller fractions. Combined brachytherapy-teletherapy regimens, especially accelerated ones, warrant further investigation, critically evaluating central blocking in advanced tumors.